Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Regeneron's Q1 Revenue and Earnings Misses

By Keith Speights – May 7, 2019 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big biotech disappointed investors in the first quarter with slower-than-expected revenue and earnings growth. Here's what you need to know.

There was some good news for investors the last time Regeneron Pharmaceuticals (REGN -1.61%) reported its quarterly results. In February, the company announced that revenue rose 22% from the prior-year period while adjusted earnings increased by 29%.

Regeneron announced its first-quarter results before the market opened on Tuesday. This time around, there was some bad news for investors. Here are the highlights of the biotech's Q1 update.

First-quarter key on keyboard

Image source: Getty Images.

By the numbers

The company's top-line performance improved in the first quarter. Revenue rose 13% year over year to $1.71 billion. Analysts had estimated that Regeneron's revenue for the quarter would come in at $1.76 billion.

The company announced Q1 GAAP net income of $461 million, or $3.99 per share. This represented a 4% decrease from GAAP earnings of $478 million, or $4.16 per share, reported in the same quarter of 2018.

On a non-GAAP adjusted basis, Regeneron's net income in the first quarter was $518 million, or $4.45 per share. This was a 4% decrease from the prior-year period adjusted net income of $537 million, or $4.67 per share. Wall Street analysts had estimated that the company would post adjusted earnings of $5.46 per share in the quarter.

Behind the numbers

As blockbuster drug Eylea goes, so goes Regeneron. Sales for the biotech's top-selling eye-disease drug increased 8.4% to $1.74 billion this quarter. 

Regeneron's partnership with Sanofi also contributed significantly to the biotech's first-quarter revenue growth. Sales for cancer drug Libtayo totaled $26.8 million. The drug won approval from the Food and Drug Administration in September 2018 for treating advanced cutaneous squamous cell carcinoma. 

Sales for Dupixent, which is approved for treating atopic dermatitis and asthma, soared 184% over the prior-year period to $373.7 million. Sales for rheumatoid arthritis drug Kevzara jumped 172% year over year to $33.7 million. However, the growth for cholesterol drug Praluent was sluggish, with sales increasing 6.7% over the prior-year period to $63.9 million. And sales for eye-disease drug Zaltrap slipped 6.8% year over year to $24.5 million.  

Regeneron's bottom line was weighed down by the company's increased spending. The biotech's research and development (R&D) costs jumped nearly 29% year over year to $641.8 million. Overall expenses grew 30% over the prior-year period's result to $1.23 billion.

Looking ahead

Regeneron now anticipates full-year 2019 GAAP Sanofi collaboration revenue to be between $500 million and $535 million, down from its previous guidance of $510 million to $560 million. The company also projected 2019 GAAP unreimbursed R&D expenses to be between $1.88 billion and $2 billion, compared to a range of $1.86 billion to $2 billion provided in its previous outlook. GAAP selling, general, and administrative (SG&A) expenses are projected to be between $1.69 billion and $1.8 billion, down from the previous guidance of between $1.7 billion and $1.83 billion.

Non-GAAP unreimbursed R&D expenses are expected to be between $1.61 billion and $1.71 billion, compared to the prior outlook of $1.59 billion to $1.71 billion.  Non-GAAP SG&A is anticipated to be between $1.5 billion and $1.58 billion, compared to the previous guidance of $1.5 billion to $1.6 billion. 

There are a couple of key regulatory decisions on the way for Regeneron. The company anticipates FDA approval for Eylea in treating diabetic retinopathy in the next few days. An FDA decision on Dupixent as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps is expected in June.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$686.10 (-1.61%) $-11.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.